XEOMIN Is Indicated for the Treatment of Upper Limb Spasticity in Children (≥2 years), Excluding Spasticity Caused by Cerebral Palsy

Flexible, Weight-Based Dosing to Fit the Needs of Your Pediatric Patients

  • XEOMIN has an extensive range of dosing options approved by the FDA, which allows for patient customization based upon the treated muscle(s)
  • XEOMIN is the only neuromodulator to provide FDA-approved pediatric dosing recommendations for 5 upper-limb clinical patterns in pediatric patients
Pinch to zoom

Dosing Frequency

Pinch to zoom

Dosing by Muscle

Pinch to zoom

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.